Educational content. This article does not provide dosing, sourcing or buying information. It explains health risks so readers can make safer decisions and recognise when someone needs help.
1P-LSD appeared in Europe around 2015 and was sold on blotter paper labelled ‘not for human consumption’. Its selling point was that it was not technically LSD. Over the past decade, scientists have studied what actually happens to 1P-LSD in the body, and their findings change how it should be understood. Our broader guide to LSD analogues and their health risks covers the whole family; this article focuses on 1P-LSD and the research behind it.
What is 1P-LSD?
1P-LSD (1-propionyl-lysergic acid diethylamide) is a lysergamide, a close chemical relative of LSD. It is LSD with an extra small chemical group attached at one position of the molecule. That small change was enough, for a time, to place it outside drug laws that named LSD specifically. It is not an approved medicine in any country.
What does the research say?
The prodrug question
A prodrug is a substance that the body converts into another, active compound. Laboratory and human studies published from around 2020 onwards found that after 1P-LSD is taken, LSD appears in the bloodstream. Researchers concluded that 1P-LSD largely acts as a prodrug for LSD, with enzymes in the body removing the added group.
Receptor and animal studies
In laboratory receptor tests, 1P-LSD itself binds less strongly to serotonin receptors than LSD. Yet in animal behaviour studies it produces psychedelic-like effects similar to LSD. This fits the idea that most of its activity comes from conversion to LSD.
What research has not settled
- How fully and how consistently the conversion happens between different people
- Long-term effects of repeated use, which have not been studied directly
- Whether products sold as 1P-LSD actually contain it, and in what amount
How does it affect the body and mind?
Because it is converted into LSD, reported effects are similar: changes in perception, thought and emotion, altered sense of time, raised heart rate and blood pressure, dilated pupils and sometimes nausea. Effects are long-lasting, which can make a difficult experience feel overwhelming.
Reported side effects
- Anxiety, panic and paranoia
- Confusion and disorientation
- Nausea and loss of appetite
- Raised heart rate and blood pressure
- Insomnia and exhaustion afterwards
- In some people, lingering visual disturbances
Main health risks
- Psychological crisis: a frightening experience can lead to accidents or dangerous behaviour.
- Mental health: psychedelics may trigger or worsen psychosis in people with a personal or family history of psychotic illness or bipolar disorder.
- HPPD: a small number of people report persistent visual changes long after use.
- Mislabelled blotters: blotters sold as LSD or its analogues have been found to contain NBOMe compounds, which are linked to seizures and deaths. Read more in our guide to 2C-B and related phenethylamines.
- New analogues: as laws change, newer variants with even less human research are released to replace banned ones.
Dangerous combinations
These are described as risks, not guidance.
- Lithium: combining lithium with LSD-type drugs has been associated with seizures.
- Tramadol: lowers the seizure threshold and may add to serotonin-related risks.
- Stimulants and MDMA: added strain on the heart and greater risk of anxiety and overheating.
- Cannabis: often reported to intensify anxiety or confusion.
- Some antidepressants and MAOIs: unpredictable interactions with serotonin systems.
Emergency warning signs
- Seizures
- Very high temperature or severe overheating
- Chest pain or irregular heartbeat
- Extreme agitation, or behaviour that puts the person or others in danger
- Unresponsiveness
What to do
- Call 112 (EU), 999 (UK) or 911 (US) if any warning sign appears.
- Place an unconscious but breathing person in the recovery position.
- Stay with them, speak calmly and reduce noise and light.
- Tell paramedics honestly what may have been taken.
- Germany: LSD derivatives have been brought under the New Psychoactive Substances Act (NpSG).
- UK: supplying it is an offence under the Psychoactive Substances Act 2016.
- Netherlands and wider EU: rules have been tightened in several countries, and the position can change quickly. Check current national law.
- US: it is not specifically scheduled federally, but it may be treated as an LSD analogue under the Federal Analogue Act when intended for human consumption.
- Netherlands: Drugs Infolijn (Trimbos Institute); DIMS drug-checking can test blotters for unexpected substances.
- UK: FRANK, 0300 123 6600.
- US: SAMHSA National Helpline, 1-800-662-4357.
- LSD Analogues (1P-LSD, 1cP-LSD, 1V-LSD, AL-LAD, LSZ): Side Effects and Health Risks
- Designer Tryptamines: Side Effects and Health Risks
- What Is 2C-B? Effects, Risks and Legal Status
- Dissociative Designer Drugs: Side Effects and Health Risks
Legal status
1P-LSD was initially sold as a legal alternative, but its status has changed in many countries:
This is a general overview and not legal advice.
Getting help
Related reading
FAQ
Is 1P-LSD safer than LSD?
There is no good evidence for this. Research suggests it is converted into LSD in the body, so its risks are broadly similar, with the added uncertainty of unregulated products.
Why do new LSD analogues keep appearing?
When one compound is banned, slightly altered versions are released to fall outside the wording of the law. Each new variant has even less safety research behind it.
Can 1P-LSD cause lasting problems?
Most people do not experience lasting effects, but some report anxiety, low mood or persistent visual disturbances. Anyone affected should speak to a doctor.
This article is for general information and is not medical advice. If you are worried about your own or someone else’s drug use, speak to a doctor or one of the services listed above.